07 / Pharmacology
How long compounds take to reach steady state
Reference documentation on how these compounds are regulated, supplied and studied. Not a vendor assessment, not a recommendation, and not personal-use instructions.
Two different clocks get collapsed into this question, and they differ by an order of magnitude. The pharmacokinetic clock is how long repeated dosing takes to reach a stable concentration, which is about five half-lives and is calculable for any compound with a published half-life. The clinical clock is how long a trial had to run before an effect was measurable, which is known only where a trial exists. For semaglutide the first is roughly five weeks and the second was 68 weeks. Reaching steady state is a statement about blood concentration and says nothing about whether anything is working.
The pharmacokinetic clock
With repeated dosing at a fixed interval, concentration accumulates until the amount cleared between doses equals the amount given. That point is steady state, and it arrives after roughly four to five half-lives regardless of the dose. A larger dose reaches a higher steady concentration, not a faster one. The distribution below is every compound in this catalog grouped by its reported half-life, with the steady-state horizon that follows from it.
Scope. This applies only to repeated dosing at a fixed interval. A single administration has no steady state, and a compound with a half-life of minutes is cleared long before the next dose.
| Reported half-life | Count | Steady state under repeated dosing |
|---|---|---|
| Under an hour | 40 | Steady state within a few hours, and the compound is effectively cleared between doses.For example: Tesamorelin, Semax, Selank, AOD-9604. |
| One to twelve hours | 14 | Steady state within about two days of repeated dosing.For example: BPC-157, Ipamorelin, Thymosin Alpha-1, Dihexa. |
| Twelve hours to two days | 5 | Steady state within roughly a week to ten days.For example: TB-500, MK-677, IGF-1 LR3, Liraglutide. |
| Two to seven days | 10 | Steady state after roughly four to five weeks of weekly dosing.For example: Tirzepatide, Semaglutide, Retatrutide, PEG-MGF. |
| Longer than a week | 2 | Steady state after more than a month, and often longer.For example: Tesofensine, Testosterone Cypionate. |
| Blend, half-life belongs to the components | 7 | A combination. Each component clears at its own rate, so the blend has no single half-life and no single steady-state horizon.For example: Wolverine, CJC-1295 + Ipamorelin, Tesamorelin + Ipamorelin, BPC-157 + KPV. |
| Topical, no systemic figure | 15 | Applied to the skin and acting locally. A plasma half-life is not the quantity that governs the effect.For example: AHK-Cu, Argireline, Decapeptide-12, Matrixyl. |
| Depot or implant | 2 | Release from the formulation is slower than clearance, so the formulation sets the duration rather than the half-life.For example: Triptorelin, Melanotan I. |
| Two forms with different half-lives | 1 | The compound ships in more than one form and the forms clear at different rates, so a single steady-state horizon would describe neither.For example: CJC-1295. |
| Not established | 14 | No half-life has been published for this compound, in humans or at all. No steady-state horizon can be stated.For example: GHK-Cu, FOXO4-DRI, Humanin, PNC-27. |
The clinical clock, where a trial exists
The compounds below carry a registration or Phase 2 readout in this catalog, so both clocks are known for them. The gap between the two columns is the answer to the question. In every case the trial ran for many multiples of the time needed to reach a stable concentration, because what the trial was measuring was a slow physiological change rather than the arrival of the drug in plasma.
| Compound | Half-life | To steady state | Trial length | Ratio | What the trial measured |
|---|---|---|---|---|---|
| Semaglutide | ~7 days | 35 days | 208 weeks | 41.6x | weight loss, n=8803PMID:38740993 |
| SS-31 | ~2-4 hrs | 19.2 hours | 168 weeks | 1176x | mitochondrial functionPMID:38602181 |
| Tirzepatide | ~5 days | 25 days | 88 weeks | 24.6x | fat loss, n=335PMID:38078870 |
| Orforglipron | ~29-49 hrs | 10.2 days | 72 weeks | 49.4x | weight loss, n=3127PMID:40960239 |
| CagriSema | ~7 days | 35 days | 68 weeks | 13.6x | weight loss, n=2108PMID:40544433 |
| Liraglutide | ~13 hrs | 2.7 days | 56 weeks | 144.7x | weight loss, n=423PMID:26284720 |
| MK-677 | ~24 hrs | 5 days | 52 weeks | 72.8x | IGF-1 changePMID:19015485 |
| Somatropin (HGH) | ~2-5 hrs (SC) | 1 day | 52 weeks | 349.4x | growth velocityPMID:36062966 |
| Retatrutide | ~6 days | 30 days | 48 weeks | 11.2x | weight loss, n=70PMID:37366315 |
| Mazdutide | Long-acting weekly | 35 days | 48 weeks | 9.6x | weight loss, n=203PMID:40421736 |
| Survodutide | Long-acting weekly | 35 days | 48 weeks | 9.6x | MASH resolution, n=73PMID:38847460 |
| Dulaglutide | ~5 days | 25 days | 40 weeks | 11.2x | HbA1c reduction, n=299PMID:29397376 |
| Cagrilintide | ~7 days | 35 days | 32 weeks | 6.4x | weight loss, n=30PMID:37364590 |
| Tesamorelin | ~26 min | 2.4 hours | 26 weeks | 182x | visceral fat reduction, n=806PMID:20554713 |
| Sermorelin | ~10-20 min | 2.4 hours | 26 weeks | 182x | growth velocity, n=86PMID:8772599 |
| PT-141 | ~2 hrs | 9.6 hours | 24 weeks | 168x | sexual desire scorePMID:31599840 |
| Cerebrolysin | Short (minutes-hours) | 2.4 hours | 13 weeks | 91x | stroke recovery ratePMID:40325343 |
| Testosterone Cypionate | ~8 days (cypionate ester) | 40 days | 12 weeks | 2.1x | body compositionPMID:40177735 |
| Enclomiphene | ~10 hrs | 2.1 days | 6 weeks | 20.2x | testosterone increase, n=48PMID:23875626 |
| ARA-290 | ~2 hrs | 9.6 hours | 4 weeks | 28x | neuropathy pain reductionPMID:23168581 |
Where neither clock is known
Most of this catalog has no trial readout at all, and for those compounds no honest figure for time to effect exists. A published half-life still gives a steady-state horizon, which is a real number about concentration, and that is the most that can be said. Any source offering a "results in two to four weeks" figure for a compound with no controlled trial is describing expectation rather than evidence.
Frequently asked questions
How long do peptides take to work?
It depends on which of two clocks is meant, and they differ by an order of magnitude. Time to steady state, meaning the point at which repeated dosing produces a stable blood concentration, is about five half-lives: a few hours for a compound cleared in minutes, and four to five weeks for one with a half-life of several days. Time to a measurable clinical effect is a separate question answered only by trials. Semaglutide reaches steady state in roughly five weeks, and the STEP 1 trial that established its weight-loss effect ran for 68 weeks. Reaching steady state is not the same as an effect appearing.
What is time to steady state, and how soon after starting is it reached?
Steady state is the point at which the amount of a compound cleared between doses equals the amount administered, so the concentration stops rising. With dosing at a fixed interval it arrives after roughly four to five half-lives, independent of the dose size. For a compound with a half-life of about seven days, dosed weekly, that is roughly five weeks. For one with a half-life of two hours it is under a day.
Does a higher dose reach steady state faster?
No. The time to steady state is set by the half-life and the dosing interval, not by the dose. A larger dose settles at a higher concentration after the same number of half-lives. This is why loading schemes exist in clinical practice: they raise the starting concentration rather than shortening the accumulation period.
Sources
Open this guide on PeptideHelper.org for the interactive version with the full guide series navigation.